Clinical Application of Chimeric Antigen Receptor Modified γδ T Cells CAR - γ δ T Cells in Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors
Latest Information Update: 07 Mar 2023
At a glance
- Drugs CD7 targeting UCAR-T cell therapy-PersonGen BioTherapeutics (Primary)
- Indications Peripheral T-cell lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Sponsors PersonGen Biotherapeutics
- 13 Jan 2021 New trial record